Novo Nordisk to Slash Ozempic and Wegovy List Prices by 50% Amid IRA Pressure

Novo Nordisk’s decision to slash the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50% represents a seismic shift in the U.S. pharmaceutical landscape. This move, announced in February 2026, is the most significant pricing concession by a major drugmaker since the implementation of the Inflation Reduction Act (IRA). For years, Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management) have been at the center of a national debate over drug affordability, with U.S. list prices often exceeding ten times those found in European markets. By cutting list prices in half, Novo Nordisk is attempting to preempt further regulatory intervention while simultaneously expanding its reach to millions of patients who remain priced out of the market.

The timing of this announcement is inextricably linked to the first round of Medicare price negotiations. Ozempic was one of the initial ten drugs selected by the Centers for Medicare & Medicaid Services (CMS) for price negotiation under the IRA, a process that has been fiercely contested by the pharmaceutical industry in federal courts. While the negotiated prices are not set to take effect until 2026, Novo Nordisk’s proactive list price reduction suggests a strategic pivot. By lowering the sticker price, the company may be looking to reduce the political pressure from lawmakers, most notably the Senate Health, Education, Labor, and Pensions (HELP) Committee, which has held high-profile hearings questioning why Americans pay significantly more for semaglutide than citizens in Denmark or Germany.

“

Novo Nordisk’s decision to slash the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50% represents a seismic shift in the U.S.

Beyond the regulatory sphere, this pricing strategy is a direct response to the intensifying competition in the GLP-1 market. Eli Lilly’s Mounjaro and Zepbound have rapidly gained market share, often competing on both clinical efficacy and aggressive pricing strategies, such as the release of single-dose vials for Zepbound at a lower price point. Novo Nordisk’s 50% cut effectively resets the baseline for the entire category. However, the impact on the company’s bottom line is complex. In the U.S. healthcare system, the list price is rarely what insurers or Pharmacy Benefit Managers (PBMs) actually pay. PBMs typically negotiate deep rebates and discounts behind closed doors. A lower list price could ironically face resistance from PBMs, whose business models often rely on capturing a percentage of the total rebate amount. If Novo Nordisk reduces the list price but also reduces the rebates, PBMs may lose their incentive to prioritize these drugs on their formularies.